LBT Innovations Limited : LBT Lodges International Patents

The Manager
Company Announcements Office
ASX Limited

LBT LODGES INTERNATIONAL PATENTS FOR NEW CULTURE PLATE INTERPRETATION TECHNOLOGY Adelaide, 16 March 2012: Clinical and diagnostic technology company LBT Innovations Limited (ASX: LBT) is pleased to announce the lodgement of multiple international patent applications for its second automated diagnostics technology, the Automated Plate Assessment System (APAS).

The lodgement on 4 March under the Patent Cooperation Treaty will bolster the commercial prospects of APAS, which automates the reading, reporting and sorting of culture plates in large microbiology laboratories. The principal hardware and software elements of the technology will now be subjected to a series of examinations by an International Searching Authority to ensure they meet certain standards of novelty and inventiveness.
The current applications bring to 14 the total number of patent and design families associated with the company's APAS
and PREVI® Isola technologies.
The MicroStreak patent family at the core of the PREVI Isola system for automated culture plate streaking has been granted in Australia, France, Germany, the United Kingdom, Italy, the Netherlands, Spain, New Zealand, China and the USA, with applications pending in further countries.
- ENDS -

About LBT Innovations

LBT Innovations is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the
Company was formed in 2004 and listed on the Australian Securities Exchange on 31 July 2006 (ASX: LBT).
In 2007, LBT Innovations signed an agreement with French diagnostics giant bioMérieux to commercialise and market its first invention, sold as PREVI® Isola, which automates the streaking of culture plates in microbiology laboratories. LBT receives milestone and royalty payments for PREVI® Isola, which has been installed in laboratories in the US, Australia, China, Japan, Korea, the Middle East, the UK and multiple European countries.
LBT's strategy is to become a leader in the automation of the international pathology laboratory with multiple products to take to that market. The company has recently unveiled its second product, APAS, which automates the screening and sorting of culture plates. LBT is now evaluating options for the commercialisation of APAS and is in discussions with leading international companies.
For more information, see www.lbtinnovations.com

CONTACTS

LBT Innovations	Media Relations
Lusia Guthrie CEO & Managing Director Tel: [phone] E: [e-mail]	Rudi Michelson Monsoon Communications Tel: [phone] E: [e-mail]

Page 1 of 1